Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boldenone undecylenate is a synthetic androgen and anabolic steroid (AAS) medication primarily used in veterinary medicine, especially for horses. It is an esterified form of boldenone, acting as a long-lasting prodrug that is administered by intramuscular injection. The drug exerts its effects by binding to the androgen receptor, leading to increased protein synthesis and muscle growth through gene transcription regulation. Boldenone undecylenate has strong anabolic effects with moderate androgenic activity and weak estrogenic properties. It was originally introduced for medical use in the 1960s but is now mainly used in animals to promote weight gain, improve appetite, and enhance physical condition following illness or overexertion. Human use has been discontinued due to side effects such as masculinization and its status as a controlled substance; it remains marketed for veterinary purposes in some countries[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on boldenone undecylenate.